Notes generated by artificial intelligence have lower-quality scores than those generated by humans across 5 standardized care cases.

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.

The FDA will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.

Older adults and immunocompromised individuals in England face a disproportionately higher burden of severe influenza outcomes and hospitalizations.

The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.

Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.

Empiric azithromycin plus β-lactam therapy reduces the composite risk of 30-day mortality and rehospitalization in nonsevere CAP.

Moderate-to-severe disability affects nearly one-third of patients with inflammatory bowel disease, according to a recent review.

Tennessee hospitalizations for injection drug use-related infections remain a major clinical and economic burden despite rates plateauing after 2018.

After months of leadership changes, President Donald Trump has chosen a new candidate to lead the CDC, Dr Erica Schwartz.

Ceftolozane-tazobactam shows a higher clinical cure rate than ceftazidime-avibactam for MDR/DTR P aeruginosa infections.

Blaine Labs recalls Revitaderm and Tridergel wound care gels due to microbial contamination with Lysinibacillus fusiformis.